Loading clinical trials...
Loading clinical trials...
Phase 1 open label dose ranging study of RH324 in advanced non-small cell lung cancer
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
ReHeva Biosciences,Inc.
NCT05142592 · Safety Issues, Tolerability, and more
NCT04861506 · Thromboembolic Disease, Lower Extremity Problem, and more
NCT06189170 · Safety Issues, Tolerance
NCT05583006 · Patient Satisfaction, Drug Adherence, and more
NCT06509490 · Safety Issues
Case Comprehensive Cancer Center University Hospitals
Cleveland, Ohio
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions